
Seven Practical Tips For Manufacturers Amid Tariff Uncertainty
But manufacturers can't afford to freeze in place. No one knows exactly what tomorrow holds when it comes to tariff rates across geographies and products, but one thing seems certain: in one form or another, tariffs are here to stay as the current administration takes a protectionist approach to global trade.
So, what can manufacturers do until the tariff rates (and turmoil) settle?
I spoke to Stephen Lovass, former executive vice president at precision technology manufacturer Nordson Corp., to get his take on how companies can stay ahead of the curve.
'Bottom line, there are options, but it's complex,' Lovass says. 'You need to communicate heavily with your customers and remain agile as the rates continue to be in flux.'
Here are seven things we identified to navigate tariffs and ongoing trade uncertainty.
The long-term tariff landscape remains murky—but waiting it out isn't a strategy. The manufacturers that act now, even amid uncertainty, will be far better positioned when the dust settles. Taking action today could mean securing more flexible contracts, diversifying suppliers, or simply building better relationships with customers that will pay off in the long run. There's no one-size-fits-all playbook, but there are plenty of smart and proactive moves that can make a real impact.
'There's challenge and opportunity here,' Lovass says. 'So, it's about knowing which side of the coin you're on and seeing how you can get on the right side.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Factbox-Healthcare firms see growing activist investor involvement in the past year
(Reuters) -Activist investors have targeted major healthcare companies over the past year to push them to improve their performance, with some campaigns only coming to light after announcements of board changes. Below are some notable healthcare companies that came under activist pressure in the last 12 months. MEDTRONIC In August 2025, the medical device maker appointed two new independent directors to its board and created independent committees focused on improving its performance, after Elliott Investment Management took a large stake, making it one of the company's biggest shareholders. AVANTOR Engine Capital targeted the life sciences firm in August 2025, urging it to bring in new board directors, cut costs and even consider a sale. CHARLES RIVER LABORATORIES The contract research firm settled with Elliott Investment Management in May 2025 by agreeing to add four new board directors and launch a strategic review of the business. NOVO NORDISK Activist hedge fund Parvus Asset Management is building a stake in the company, as investors have grown concerned that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss drug market, the Financial Times reported in June 2025. Reuters has not independently verified the report. GERRESHEIMER London-based investment fund Asset Value Investors in June 2025 pressed the German medical packaging maker to find ways to restore its market value. AVI, with a 3.5% stake in Gerresheimer, said the company needs a new financial leadership to regain its credibility. ILLUMINA In March 2025, the gene-sequencing maker said activist investor Keith Meister would join its board. HENRY SCHEIN In January, private equity firm KKR built a large stake in the medical and dental supplies distributor and reached a deal to add members to the company's board. Henry Schein was also under pressure from other investors, including Ananym Capital Management. PFIZER Activist hedge fund Starboard Value in October 2024 called for management accountability for the company's underperformance. This month, Starboard increased its holding in the drugmaker to 8.5 million shares, which represented about 0.15% of the outstanding shares as of June end. KENVUE In October 2024, Starboard Value took a significant stake in the Band-Aid maker, criticizing the weak performance of its skin health segment, which houses Neutrogena, Aveeno and other brands. After a proxy battle, the companies reached a deal in early 2025 that gave Starboard CEO Jeffrey Smith and two independent directors board seats. CVS HEALTH In November, CVS Health added Glenview Capital's top boss and three others to its board as part of a deal with the hedge fund. The company had been under pressure from investors, including Glenview, to improve operations after missing financial targets several times due to rising medical costs in its health insurance business. Glenview reduced its stake in the company after CVS posted strong results in May. Sign in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio
Yahoo
4 minutes ago
- Yahoo
Hemostemix's Social Media for Investors and Florida's No-Option Patients
Calgary, Alberta--(Newsfile Corp. - August 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering treatments for no-option patients in Florida suffering from Chronic Limb Threatening Ischemia, Peripheral Arterial Disease, Angina, Ischemic Cardiomyopathy, non Ischemic Dilated Cardiomyopathy, and Congestive Heart Failure, is pleased to announce additions to its investor awareness and social media strategies and programs. The investor outreach campaign includes: Opt-in SMS alerts to keep existing and prospective investors updated on corporate milestones - text 905-580-4170 to opt-in. Targeted opt-in email provides company news, clinical developments, and financing updates: email: sfarooquoi@ Investor platforms and exchanges ( are designed to increase Hemostemix's visibility, providing due diligence level information that retail and institutional audiences seek about our Company's investment opportunities. "Hemostemix has sold forward $1,143,983 in Therapy Convertible Debenture year-to-date," said Thomas Smeenk, CEO. "Frost and Sullivan awarded our Company the Biotechnology Company of the Year Award, Asia, in 2007, for VesCell™ achievements. Now, with 498 treatments, 11 peer reviewed publications including 7 clinical studies of 318 subjects, including Phase II results that validate our patients' testimonials, we are ramping up sales in Florida, investor outreach, and patient engagement simultaneously. VesCell™ won the World Economic Forum Technology Pioneer Award because it regenerates new circulation in the body where that need is signaled. Next week, I'm down to Florida to meet with cardiologists who have done their homework - stay tuned" Smeenk said. Campaign Strategy & Key Highlights - Testimonials and Publications Storytelling: Real patient testimonials about improved cardiac function, reduction of pain and ulcer healing make the science and treatment relatable and compelling. TIME Magazine highlighted VesCell™ recipient, Bob Grinstead, in Take Heart. Watch six time Grammy award winner and VesCell™ recipient Howie Lindeman. Watch Beefsto's Founder, VesCell™ patient #57, Neim Malo. Platform Utilization: Instagram & Facebook: Hemostemix has shared emotionally driven visuals and success narratives to connect directly with patients, caregivers, and broader communities. LinkedIn: Tailored for professionals and investors—Hemostemix is highlighting our clinical milestones, innovations, and corporate positioning. X: Thomas Smeenk, CEO, @HeartRepairGuy, is providing quick, timely updates, and engagement with practitioners and investor audiences. YouTube: Hemostemix posts its longer-form video content including its weekly webinars and VesCell™ patient testimonials: Results Emphasized in Posts: Cardiac Improvements of up to a 47.1% increase in ejection fraction (LVEF%) in dilated cardiomyopathy patients after one treatment, Schubart et al, Stem Cell Research and Therapy. Phase II CLTI: a 99% reduction in ulcerating wounds size, reduced from a mean of 146 mm² to 0.48 mm² by the end of month three (p=0.01), Henderson et al, JBRES1876. Dual Audience Targeting: The campaign bridges two primary goals: Patient Recruitment: Demonstrating hope, safety, and effectiveness of VesCell™ for no-option CLTI, PAD, and heart patients. Liquidity for Investors: Educating investors and shareholders about the HEM's asymmetrical investment upside, using scientifically validated results and milestones achieved. Summary Table Platform Primary Focus Instagram Visual stories of healing and clinical transformation Facebook Patient-centric storytelling and community engagement LinkedIn Corporate, investor, and scientific communications YouTube In-depth video testimonials and informational content X Brief updates, engagement with the medical & investor audience ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@ / PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the Company's social media campaign strategy in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data